Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryJapanJapan
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

Progabide

Progabide
Contact us for more batch information
Select Batch
Purity:99.7%
Resource Download

Progabide

Catalog No. T16581Cas No. 62666-20-0
Progabide (SL 76002) is an agonist of the gamma-aminobutyric acid receptor.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Pack SizePriceAvailabilityQuantity
5 mg$47In Stock
10 mg$80In Stock
25 mg$163In Stock
50 mg$263In Stock
100 mg$413In Stock
200 mg$590In Stock
500 mg$943In Stock
1 mL x 10 mM (in DMSO)$52In Stock
Bulk & Custom
Add to Cart
Questions
View More

Related Compound Libraries of "Progabide"

Product Introduction

Bioactivity
Description
Progabide (SL 76002) is an agonist of the gamma-aminobutyric acid receptor.
In vivo
Progabide ( 50, 100 and 200 mg/kg) given IP to male Wistar rats enhance the plasma corticosterone levels by 244, 365, and 476% respectively (t=6.44 to12.55, p<0.01). Progabide (10 mg/kg) fails to change the concentration of corticosterone in plasma (t=0.76, N.S.). The increased plasma corticosterone level induced by administration of 200 mg/kg Progabide is evident 30 (t=2.625, p<0.05), 60 (t=13.13, p<0.001) and 120 min (t=4.07, p<0.01) after drug injection, but returns to the control value 240 min after drug injection (t=0.86, N.S.). Compare with the corresponding control, The greatest corticosterone rise is reached 60 min following the administration of Progabide[1].
AliasSL 76002, Halogabide, Gabren, Gabrene
Chemical Properties
Molecular Weight334.77
FormulaC17H16ClFN2O2
Cas No.62666-20-0
Storage & Solubility Information
Storagekeep away from direct sunlight Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Solubility Information
DMSO: 225 mg/mL (672.1 mM)
Solution Preparation Table
DMSO
1mg5mg10mg50mg
1 mM2.9871 mL14.9356 mL29.8713 mL149.3563 mL
5 mM0.5974 mL2.9871 mL5.9743 mL29.8713 mL
10 mM0.2987 mL1.4936 mL2.9871 mL14.9356 mL
20 mM0.1494 mL0.7468 mL1.4936 mL7.4678 mL
50 mM0.0597 mL0.2987 mL0.5974 mL2.9871 mL
100 mM0.0299 mL0.1494 mL0.2987 mL1.4936 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
%Tween 80
%ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords